Drug – bio-affecting and body treating compositions – Dentifrices
Reexamination Certificate
2005-09-20
2005-09-20
Webman, Edward J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Dentifrices
C424S464000, C424S489000, C424S484000, C424S450000, C424S046000, C424S435000
Reexamination Certificate
active
06946118
ABSTRACT:
Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. Such compositions have the advantage of treating the entire gastro-intestinal tract since the active ingredient is not removed from the tract via absorption. Further, such compositions minimize systemic exposure and accompanying side effects.
REFERENCES:
patent: 3966808 (1976-06-01), Luciano
patent: 4961926 (1990-10-01), Gabrilove
patent: 5082653 (1992-01-01), Pan et al.
patent: 5102870 (1992-04-01), Florine et al.
patent: 5284963 (1994-02-01), Sum et al.
patent: 5328902 (1994-07-01), Sum et al.
patent: 5386041 (1995-01-01), Sum et al.
patent: 5401729 (1995-03-01), Sum et al.
patent: 5420272 (1995-05-01), Sum et al.
patent: 5430162 (1995-07-01), Sum et al.
patent: 5545668 (1996-08-01), Skubitz et al.
patent: 5635489 (1997-06-01), Haley
patent: 5827840 (1998-10-01), Ramamurthy et al.
patent: 5886175 (1999-03-01), Sum et al.
patent: 5945089 (1999-08-01), Libin
patent: 5981499 (1999-11-01), Hau
patent: 6025326 (2000-02-01), Steinberg et al.
patent: WO 94/27579 (1994-12-01), None
patent: WO 98/18610 (1998-05-01), None
patent: WO 99/22703 (1999-05-01), None
patent: WO 99/45910 (1999-09-01), None
patent: WO 00/07601 (2000-02-01), None
Barker, et al., “Oral care with vancomycin paste for reduction in incidence of alpha-hemolyticStreptococcal sepsis,” J Pediatr Hematol Oncol 17(2):151-55 (1995).
Cartee, et al., “Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study,”Cytokine7(5):471-7 (1994).
Chi, et al., “Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy,”J. Clin. Oncol.13(10):2620-28 (1995).
Epstein & Wong, “The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy,”Int. J. Radiat. Oncol. Biol. Phys.28(3):693-98 (1994).
Epstein, et al., “Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy,”Oral Surg. Oral Med. Oral Pathol.62(2):145-8 (1986).
Epstein, et al., “Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse,”Int. J. Radiation Oncology Biol. Phys.16(6):1571-5 (1989).
Essentials of Medicinal ChemistryJohn Wiley and Sons, Inc., pp 512-517 (1976).
Ferretti, et al., “Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse,”Bone Marrow Transplant3(5):483-93 (1990).
Foote, et al., “Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis,”J. Clin Oncol.12(12):2630-33 (1994).
Loprinzi, et al., “Alleviation of cytotoxic therapy-induced normal tissue damage,”Sem. Oncol.22(2) Suppl. 3:95-97 (1995).
Mitscher, et al., “Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids,”J. Med. Chem.21(5):485-9 (1978).
Sonis, 1993b, “Oral Complications in Cancer Therapy,” In:Principles and Practice of Oncology,De Vitta et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).
Special Care in DentistryJan.-Feb., pp. 21-25 (1990).
Spijkervet, et al., “Chlorhexidine inactivation by saliva,”Oral Surg. Oral Med. Oral Pathol.69(4):444-49 (1990).
Verdi, et al., “A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis,”Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.80(1):36-42 (1995).
Weisdorf, et al., “Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse,”Bone Marrow Transplant4(1):89-95 (1989).
Cutler & Schubert, “Patient factors affectingHelicbacter pylorieradication with triple therapy,”American Journal of Gastroenterology88(4):505-509 (1993).
Facchini, et al., “Attivita di flunoxaprofene per uso topico nelle vaginiti aspecifiche. Confronto con meclociclina solfosalicilato,”Minerva Ginecologica41(12):609-614 (1989).
Franceschi, et al., “Solitary J-pouch ulcer causing pouchitis-like syndrome,”Diseases of the Colon and Rectum29(8):515-517 (1986).
Rothwell & Spektor, “Palliation of radiation-related mucositis,”Special Care in Dentistry10(1):21-25 (1990).
Schenk, et al., “Controlled local delivery of tetracycline HCI in the treatment of periimplant mucosal hyperplasia and mucositis,”Clinical Oral Implants Research8(5):427-433 (1997).
Comiskey Stephen J.
Lawter James Ronald
Clark & Elbing LLP
Orapharma, Inc.
Webman Edward J.
LandOfFree
Formulations for treating or preventing mucositis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations for treating or preventing mucositis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for treating or preventing mucositis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3369523